Direkt zum Inhalt
Merck
  • Rationalization of the inhibition activity of structurally related organometallic compounds against the drug target cathepsin B by DFT.

Rationalization of the inhibition activity of structurally related organometallic compounds against the drug target cathepsin B by DFT.

Dalton transactions (Cambridge, England : 2003) (2010-05-15)
Angela Casini, Fabio Edafe, Mikael Erlandsson, Luca Gonsalvi, Antonella Ciancetta, Nazzareno Re, Andrea Ienco, Luigi Messori, Maurizio Peruzzini, Paul J Dyson
ZUSAMMENFASSUNG

A series of organometallic compounds of general formula [(arene)M(PTA)(n)X(m)]Y (arene = eta(6)-C(10)H(14), eta-C(5)Me(5)); M = Ru(ii), Os(ii), Rh(iii) and Ir(iii); X = Cl, mPTA; Y = OTf, PF(6)) have been screened for their cytotoxicity and ability to inhibit cathepsin B in vitro, in comparison to the antimetastatic compound NAMI-A. The Ru and Os analogues and NAMI-A showed similar enzyme inhibition properties (with IC(50) values in the low muM range), whereas the Rh(iii) and Ir(iii) compounds were inactive. In order to build up a rational for the observed differences, DFT calculations of the metal complexes adducts with N-acetyl-l-cysteine-N'-methylamide, a mimic for the Cys residue in the cathepsin B active site, were performed to provide insights into binding thermodynamics in solution. Initial structure-activity relationships have been defined with the calculated binding energies of the M-S bonds correlating well with the observed inhibition properties of the compounds.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Cathepsin B aus Rindermilz, lyophilized powder, ≥10 units/mg protein